EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View Beyond Cetuximab

Chemotherapy Research and Practice

doi 10.1155/2012/901320

Full Text

Abstract

Available in

Date

Authors

Publisher

Hindawi Limited

Related search

Recent Results of Cetuximab Use in the Treatment of Squamous Cell Carcinoma of the Head and Neck

OncoTargets and Therapy
OncologyPharmacology
2009English

EGFR Modulates Complement Activation in Head and Neck Squamous Cell Carcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck

American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer ResearchOncology
2016English

PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2009English

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Journal of Skin Cancer
DermatologyOncology
2011English

Detection of EGFR- And HER2-activating Mutations in Squamous Cell Carcinoma Involving the Head and Neck

Modern Pathology
Forensic MedicinePathology
2006English

Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Nicotine Promotes Lymph Node Metastasis and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma

International Journal of Oncology
Cancer ResearchOncology
2018English

Aberrant HER3 Ligand Heregulin-Expressing Head and Neck Squamous Cell Carcinoma Is Resistant to Anti-Egfr Antibody Cetuximab, but Not Second-Generation EGFR-TKI

Oncogenesis
Cancer ResearchMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy